Articles by Camille Mojica Rey

  1. CEOs 40 & Under: The Future of Pharma Innovation 7/7/2017

    To take the pulse of the biopharma industry, Life Science Leader tracked down four CEOs age 40 and under. These are the people at the forefront of innovation — something that is no easy task in a heavily regulated, patient-centered industry. Biotech is not tech. Heading up a company that is developing a pharmaceutical is a lot more challenging and riskier than starting one in your garage that is developing the next mobile phone app.

  2. Can DalCor Pharma Succeed Where Others Have Failed? 6/7/2017

    After the worldwide success of statins, no one expected the epic failure of a class of drugs designed by the biggest names in Big Pharma to double the reduction in cardiac risk seen with statins alone. Statins lowered LDL, the bad cholesterol. The new drugs, called cholesteryl ester transfer protein (CETP) inhibitors, would raise HDL, the good cholesterol. Taken together, the drugs would reduce risk of cardiovascular events by up to 80 percent — or at least that was the idea.

  3. Amorsa's Self-Funded Path To Big Pharma Partnerships 6/7/2017

    Amorsa Therapeutics has accomplished something rare — if not unheard of. The company, founded in 2013, was self-funded for three years before entering into a strategic partnership with Janssen Pharmaceuticals in January 2017. This journey was made possible by industry experience, scientific expertise, and rock-solid confidence in their choice of therapeutic target.

  4. Awakening The Biotech Entrepreneurial Spirit 6/7/2017

    Roger Newton still remembers the day in November of 1997 when he tripped over a pile of books in a Borders Bookstore in Ann Arbor, MI. He looked down on a back cover of one of the books to see the words: “Don’t let your company kill you.” He turned the book over and saw the title of Robert E. Quinn’s book, Deep Change: Discovering the Leader Within. His life and career would never be the same.

  5. Is Marking Individual Doses The Future Of Anticounterfeiting? 5/12/2017

    The last in our five-part series examining the current state of the counterfeit medicines problem. Previous stories looked at efforts to quantify the crime, examined the issue from the perspective of the industry giant Pfizer, described how an international coalition is fighting the crime, and highlighted the latest programs aimed at teaching the public how to safely shop for medicines online.